# Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

> **NCT05659056** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 65 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib, trastuzumab, paclitaxel-albumin

## Key facts

- **NCT ID:** NCT05659056
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-29
- **Primary completion:** 2024-04
- **Final completion:** 2024-07
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659056, "Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05659056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*